The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of pleural effusion (PE) on treatment adherence, discontinuation, switching, and dose modification in patients with chronic myelogenous leukemia (CML).
E. Q. Wu
Employment or Leadership Position - Analysis Group
A. Guerin
Employment or Leadership Position - Analysis Group
V. K. Bollu
Employment or Leadership Position - Novartis
A. Guo
Employment or Leadership Position - Novartis
M. Cloutier
Employment or Leadership Position - Analysis Group
D. Ponce de Leon Barido
Employment or Leadership Position - Analysis Group
S. Ericson
Employment or Leadership Position - Novartis
A. Quintas-Cardama
Consultant or Advisory Role - Novartis